•
Sep 30, 2020
Ocugen Q3 2020 Earnings Report
Ocugen reported a net loss for the third quarter of 2020, with progress made in developing gene therapy and biologic product candidates.
Key Takeaways
Ocugen reported third quarter 2020 financial results with a net loss of $10.5 million, or $0.07 per share. The company's cash, cash equivalents, and restricted cash totaled $19.3 million as of September 30, 2020. Ocugen is on track to initiate four Phase 1/2a trials during 2021 and 2022.
Made steady progress towards starting OCU400 clinical trials in 2021.
Entered into a manufacturing contract for OCU200 with Kemwell Biopharma.
Fully repaid unsecured notes.
Raised capital of $10.1 million net proceeds in the third quarter, increasing its cash runway into the third quarter of 2021.